Allergan Plc was sued by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease.

A Native American tribe holding patents for drugmaker Allergan Plc moved to dismiss a case brought by generic drug company Mylan NV challenging the patents.

The hope of new measures for the FDA to advance the regulatory path for drug development is forging ahead incorporating relatively swift pivotal data in seeking accelerated approvals.

Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.

A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition.

Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.

North Carolina-based Parion Sciences snagged a deal worth up to $535 million from Shire for its experimental dry eye disease treatment, P-321.

U.S. generic drug company Argentum Pharmaceuticals LLC said it reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan’s eye drug Restasis.

“Before we had our voice, we had our eyes,” is the powerful opening message from Allergan’s new campaign to raise awareness for chronic dry eye. The campaign, titled “Eyepowerment,” aims to empower individuals who may be struggling with symptoms of chronic dry eye to talk to their doctor.

Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.